AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 21 min read$RXRX

Borgeson Blake sold $100K of RXRX

Borgeson Blake sold 30,000 shares of RECURSION PHARMACEUTICALS, INC. (RXRX) at $3.34 ($0.10M total) on 2026-09-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Borgeson Blake
Published Sep 2, 2026, 10:01 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 2, 2026, 10:38 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$RXRX
Neutral
medium confidence
Mentioned
$RXRX
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$RXRXNeutralLow
01

Why it matters

The disclosed sale provides fresh data on insider activity, but its modest size limits trading significance.

02

Market read

New insider sale information; low immediate trading impact.

03

What to watch

Potential upcoming clinical data releases or financing activities not disclosed in the filing.

Relevance 3/10Novelty 4/10Timing: post‑market 2026‑09‑02

Background

Form 4 filings disclose insider transactions; directors often use 10b5-1 plans for scheduled sales.

Company-level read

Ticker impact

$RXRXNeutralMedium confidence
Context

Director Borgeson Blake sold 30,000 shares for $100,200 via a 10b5-1 plan, reducing his holdings to 6,158,287 shares.

Expected impact

Potential modest downward pressure on RXRX in the short term.

Evidence & confidence

The sale size is modest relative to total holdings and market cap, limiting material impact.

Market effects

Sector

Minimal effect on the biotech sector; insider sales are common and rarely move the industry.

Regional

No regional impact beyond the company's own stock.

Global

Limited global relevance; only relevant to RXRX investors.

Counterpoint

What could challenge this read

The sale could be a routine liquidity move, not a negative signal.

Key entities

  • Company
    Recursion Pharmaceuticals, Inc.

    Biotech firm listed on Nasdaq (RXRX).

  • Director
    Borgeson Blake

    Company director executing a pre‑arranged sale.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

RXRX insider trading history →

Related articles

SEP 4
$RXRXMed

RXRX Stock Steadies As AI Drug Engine Tightens Spending

Recursion Pharmaceuticals (RXRX) shares rose 5.81% on AI-driven drug discovery progress. The company reported $74.3M revenue, negative margins, and $545M in cash. Genentech optioned a neuroscience target, and RXRX cut FY26 spending to $375M, extending cash runway to early 2028. Analysts have mixed views, with an average price target of $7.22.

stockstotrade.com3 min
SEP 4
$RXRXMed

RXRX Tightens Cash Burn As AI Drug Pipeline Advances

Recursion Pharmaceuticals (RXRX) stock rose 5.96% on September 4, 2026, to $3.64, driven by AI drug discovery advancements. The company reported Q2 2026 revenue of $7.3M, a net loss of $131M, and $545M in cash. RXRX reduced its FY26 expense guidance to $375M, reflecting tighter cost management. Analysts' average price target is $7.22, with tangible clinical and partnership catalysts on the horizon.

stockstotrade.com4 min
SEP 4
$RXRXMed

RXRX Tightens Costs As AI Drug Pipeline Advances

Recursion Pharmaceuticals Inc. (RXRX) stock rose 5.83% on positive AI drug discovery progress. The company reported Q2 revenue of $74.3M, negative margins, and cash burn of -$106M, but has $545.7M in cash. RXRX guided 2026 cash operating expenses to $375M, down 40% from 2024. Analysts have mixed views, with Morgan Stanley trimming its target to $5.30 but the Street's average at $7.22.

timothysykes.com2 min
AUG 25
$RXRXMed

RXRX Stock Rallies As AI Drug Platform Tightens Cash Burn

Recursion Pharmaceuticals (RXRX) stock rose 7.23% on August 25, 2026, driven by AI-driven drug discovery progress. The company reported Q2 revenue of $7.7M, a net loss of $131M, and holds $545.7M in cash. Analysts have mixed views, with a mean price target of $7.22. RXRX is advancing its pipeline and cut FY26 cash burn guidance to $375M, extending its runway into early 2028.

stockstotrade.com3 min